ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. “We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical technology compani ...

Core Insights - RxSight, Inc. will report its financial results for Q2 2025 on August 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on customized vision solutions for patients post-cataract surgery [3] - The company offers the RxSight® Light Adjustable Lens system, which is the first and only intraocular lens technology that can be adjusted after surgery [3] - This technology allows doctors to provide tailored high-quality vision to patients following cataract procedures [3] Contact Information - Chief Financial Officer: Shelley B. Thunen, Email: sthunen@rxsight.com [4] - VP, Investor Relations: Oliver Moravcevic, Email: omoravcevic@rxsight.com [4]

Core Viewpoint - RxSight, Inc. has announced preliminary financial results for Q2 2025, indicating a decrease in revenue and a revised full-year guidance, while also focusing on enhancing customer success and engagement with clinical partners [1][3]. Preliminary Second Quarter 2025 Results - Preliminary revenue for Q2 2025 is expected to be approximately $33.6 million, a decrease of 4% year-over-year and an 11% decrease compared to Q1 2025 [8]. - The company sold 27,380 Light Adjustable Lenses (LAL®/LAL+®), reflecting a 1% decrease in procedure volume from Q1 2025 but a 13% increase from Q2 2024 [8]. - The sale of 40 Light Delivery Devices (LDD™s) saw a significant decline, with a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024 [8]. - As of June 30, 2025, the installed base of LDDs increased to 1,084, a 34% growth from 810 LDDs at the end of Q2 2024 [8]. Revised 2025 Guidance - Full-year revenue guidance has been revised downward to a range of $120.0 million to $130.0 million, a decrease from the previous range of $160.0 million to $175.0 million, implying a decrease of 14% to 7% compared to 2024 [9]. - Gross margin guidance has been increased to a range of 72% to 74%, up from the previous range of 71% to 73%, representing an increase of 130 to 330 basis points compared to 2024 [9]. - Operating expense guidance is set between $145.0 million and $155.0 million, indicating an increase of 7% to 14% compared to 2024, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million [9].

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Stifel Virtual Ophthalmology Forum on May 27, 2025, featuring a fireside chat with management [2] Company Overview - RxSight offers the RxSight® Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL®/LAL+®) and the Light Delivery Device (LDD™), the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling personalized vision outcomes for cataract surgery patients [3] Event Participation - The management of RxSight is scheduled for a fireside chat at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time on May 27, 2025 [2] - A live and archived webcast of the presentation will be accessible on the company's investor relations website [2]

Core Insights - RxSight, Inc. will report its financial results for Q1 2025 on May 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on customized vision solutions for patients post-cataract surgery [3] - The company's flagship product, the RxSight® Light Adjustable Lens system, is the first and only intraocular lens technology that can be adjusted after surgery, allowing for tailored vision correction [3] Conference Call Details - Participants can join the conference call by dialing (800) 715-9871 or (646) 307-1963, using conference code: 8740296 [2] - The call will be available in listen-only mode via the company's investor relations website, with an archived recording accessible shortly after the call [2]